Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Iberdomide in combination with dexamethasone for multiple myeloma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.09.19
Views: 718

Prof Sagar Lonial - Winship Cancer Institute, Atlanta, USA

Prof Sagar Lonial talks to ecancer at the International Myeloma Workshop 2019 about iberdomide.

Iberdomide is a novel cereblon E3 ligase modulator with enhanced tumoricidal and immunostimulatory activities.

It overcomes IMiD immunomodulatory drug resistance and has synergy with daratumumab, bortezomib, and dexamethasone.

Prof Lonial outlines some of the data from the trial focussing on the combination with dexamethosone, as well as toxicity profile.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation